BiotechTube

Alemtuzumab + Rabbit Anti-Human Thymocyte Globulin

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreas-Kidney Transplantation

Conditions

Pancreas-Kidney Transplantation

Trial Timeline

Apr 1, 2006 → Jun 1, 2011

NCT ID
NCT00316810

About Alemtuzumab + Rabbit Anti-Human Thymocyte Globulin

Alemtuzumab + Rabbit Anti-Human Thymocyte Globulin is a phase 3 stage product being developed by Astellas Pharma for Pancreas-Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00316810. Target conditions include Pancreas-Kidney Transplantation.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00316810Phase 3Completed

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85